8-KOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Apr 4, 2022)

Filed April 4, 2022For Securities:ALNY

Summary

Alnylam Pharmaceuticals announced on April 4, 2022, that the U.S. Food and Drug Administration (FDA) has extended the review period for its New Drug Application (NDA) for vutrisiran. This extension, pushing the Prescription Drug User Fee Act (PDUFA) action date to July 14, 2022, is for three months. The delay is attributed to the need for FDA review of an amendment to the submission, which addresses a pending inspection classification at a third-party secondary packaging and labeling facility. A new facility has been identified and added to the submission, necessitating this additional review time. Importantly, the company emphasized that no inspection observations were directly related to vutrisiran itself, nor has the FDA requested any additional clinical data. This suggests the delay is procedural, related to the packaging and labeling process rather than the drug's efficacy or safety profile. Investors should monitor the updated PDUFA date closely for potential approval of vutrisiran.

Key Highlights

  • 1FDA extends vutrisiran review timeline by 3 months.
  • 2New PDUFA action date set for July 14, 2022.
  • 3Extension is due to review of an amendment addressing a third-party packaging/labeling facility's inspection classification.
  • 4A new secondary packaging and labeling facility has been incorporated into the submission.
  • 5No inspection observations were directly related to vutrisiran.
  • 6FDA has not requested any additional clinical data for vutrisiran.

Frequently Asked Questions

The FDA extended the review timeline by three months to review an amendment to the existing regulatory submission. This amendment addresses a pending inspection classification at a third-party secondary packaging and labeling facility, and a new facility has been identified and incorporated into the submission.

No, the company explicitly stated that no inspection observations were directly related to vutrisiran, and the FDA has not requested any additional clinical data. The delay is procedural and related to the packaging and labeling process at a third-party facility.

The updated Prescription Drug User Fee Act (PDUFA) action date, allowing for this additional review, is July 14, 2022.

It implies that the original facility used for secondary packaging and labeling did not meet certain inspection standards, or there was a need to switch to a new, approved facility. This change required the company to update its regulatory submission, which the FDA now needs to review.